SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients
Valentina Serafin(University of Modena and Reggio Emilia), Benedetta Accordi(University of Padua)
Cited by 10
Related Papers
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia
|Clinical Cancer Research|2018|95
Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL
|PLoS ONE|2010|48
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
|Haematologica|2018|32
Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia
|Science Advances|2022|15
USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2018|5